Nurotron receives approval for sale in India

23 February 2015 | News | By BioSpectrum Bureau

(Photo Courtesy: www.walldatabase.com)

The system is a safe, reliable and effective solution for children and adults suffering from severe and profound hearing loss.

Headquartered in New Delhi, CDSCO is India's main regulatory body for pharmaceuticals and medical devices.

CDSCO organization safeguards and enhances the public health by assuring the safety, efficacy and quality of drugs, cosmetics and medical devices.

"This approval by India's primary drug and medical device oversight organization is a major achievement for Nurotron's cochlear implant system," says Mr Chu Li, CEO, Nurotron. "The validation of the efficacy of Nurortron's offerings in the important Indian market confirms the company's position as a global leader in cochlear implant technology."

Nurotron already holds the CE mark in Europe for the Venus Cochlear Implant System, and has received approval to sell in China and Turkey as well.